• CCS Authors Team

CCS members publish new tumor suppressor function of IL6/STAT3 with implications for prostate cancer

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. In a collaborative effort, CCS members from the Kenner and Aberger lab show that inactivation of IL6/STAT3 signalling unexpectedly accelerates cancer progression leading to metastasis. Mechanistically, STAT3 directly controls the p19ARF tumor suppressor inducing senescence. STAT3 and ARF therefore representnovel be prognostic markers to stratify high from low risk PCa patients. The findings also challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition. read the full article


Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria


Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria